Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib vs Cyclosporine for Steroid-Refractory Acute Severe Ulcerative Colitis
NCT05112263Not yet recruiting
- Sponsor
- Post Graduate Institute of Medical Education and Research
- Start
- Jul 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of tofacitinib oral solution in ulcerative colitis (UC) (2 arms), sponsored by Post Graduate Institute of Medical Education and Research. Primary endpoint: Treatment failure at 14 weeks. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
tofacitinib oral solution
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05112263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05112263.